5-(羟甲基)-[2,2]-联噻吩 | 3515-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 双噻吩和低聚噻吩
• 中文名称: 5-(羟甲基)-[2,2]-联噻吩
• 中文别名: [2,2']-联硫苯基-5-基甲醇
• 英文名称: 5-hydroxymethyl-2,2'-bithiophene
• 英文别名: 5-(Thien-2-yl)-2-hydroxymethylthiophene；[4-(thien-2-yl)-thien-2-yl]methanol；5-hydroxymethyl bithiophene；2,2'-bithien-5-ylmethanol；2,2'-bithiophene-5-methanol；(5-Thiophen-2-ylthiophen-2-yl)methanol
• CAS: 3515-30-8
• 化学式: C₉H₈OS₂
• mdl: MFCD02681900
• 分子量: 196.294
• InChiKey: PUWTXRUXHPHFSQ-UHFFFAOYSA-N

物化性质

• 熔点：
  51 °C
• 沸点：
  327.2±32.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  76.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 安全说明：
  S24/25

SDS

Name:	[2 2 ]Bithiophenyl-5-yl-methanol 97% Material Safety Data Sheet
Synonym:
CAS:	3515-30-8

Section 1 - Chemical Product MSDS Name:[2 2 ]Bithiophenyl-5-yl-methanol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3515-30-8	[2,2']Bithiophenyl-5-yl-methanol	97	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3515-30-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 43 - 45 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8OS2
Molecular Weight: 196

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3515-30-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
[2,2']Bithiophenyl-5-yl-methanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 3515-30-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3515-30-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3515-30-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(羟甲基)-[2,2]-联噻吩 在 对甲苯磺酸 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以58%的产率得到5,5''-(oxybis(methylene))di-2,2'-bithiophene
  参考文献：
  名称：

  Krishnaswamy, N. R.; Kumar, Ch. Siva Sai Kamana; Prasanna, S., Journal of Chemical Research, Miniprint, 1991, # 7, p. 1801 - 1830

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2'-联二噻吩 在 sodium tetrahydroborate 、 lithium diisopropyl amide 作用下， 以 乙醇 为溶剂， 反应 5.5h， 生成 5-(羟甲基)-[2,2]-联噻吩
  参考文献：
  名称：

  Novel protein kinase C inhibitors: synthesis and PKC inhibition of β-substituted polythiophene derivatives

  摘要：

  A series of beta-substituted polythiophene derivatives was synthesized through palladium-catalyzed coupling reaction. Their structure-protein kinase C (PKC) inhibitory activity relationship was studied. The carboxaldehyde and hydroxymethyl derivatives of alpha-terthiophene were potent PKC inhibitors (IC50 = 10(-7) M). (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00375-3

文献信息

• Synthesis of Thiophene-Substituted 3<i>H</i>-Naphtho[2,1-<i>b</i>]pyrans, Precursors of Photomodulated Materials
  作者：Corinne Moustrou、Nicole Rebière、André Samat、Robert Guglielmetti、Abd Errahim Yassar、Roger Dubest、Jean Aubard

  DOI：10.1002/hlca.19980810540

  日期：——

  The synthesis of 3H-naphtho[2,1-b]pyrans 9–21 linked to a thiophene moiety is described. Two different synthetic approaches were applied to prepare these novel functionalized compounds, and their spectrokinetic properties in solution are reported.

  3的合成ħ -萘并[2,1- b ]吡喃9 - 21连接于噻吩部分进行说明。两种不同的合成方法被用于制备这些新颖的功能化化合物，并报道了它们在溶液中的光谱动力学性质。
• Medicinal thiophene compounds
  申请人：Industrial Technology Research Institute

  公开号：US05747525A1

  公开（公告）日：1998-05-05

  A method of treating tumor including administering to a subject an effective amount of a compound of the following formula: ##STR1## wherein m is 1-4; and each of A and B, independently, is H, C.sub.1-7 alkyl, C.sub.2-7 alkenyl, C.sub.2-7 alkynyl, (CH.sub.2).sub.n CHO, (CH.sub.2).sub.o COOH, C.sub.1-7 alkoxy, C.sub.2-7 alkoxyalkyl, C.sub.1-7 hydroxyalkyl, CN, NO.sub.2, halogen, CH(OR.sup.1).sub.2, CO.R.sup.1, NR.sup.2 R.sup.3 or its acid salt, CO.NR.sup.2 R.sup.3, CHR.sup.1 NR.sup.2 R.sup.3 or its acid salt, CH.dbd.NR.sup.2, C.tbd.CR.sup.4, CR.sup.1 .dbd.CR.sup.5 R.sup.6, CO.CH.dbd.CHR.sup.7, CH.dbd.CHR.sup.8, or COOR.sup.9 ; in which each of n and o, independently, is 0-4; R.sup.1 is C.sub.1-4 alkyl or C.sub.1-4 acyl; each of R.sup.2 and R.sup.3, independently, is H, C.sub.1-4 alkyl, or C.sub.1-4 hydroxyalkyl; R.sup.4 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, COR.sup.2, COOR.sup.10, C.sub.1-4 hydroxyalkyl or its acid ester or 2-tetrahydropyranyl ether, C.sub.1-4 dihydroxyalkyl or its acid ester or 2-tetrahydropyranyl ether, C.sub.1-4 halogenated alkyl; OR.sup.1, or NHR.sup.7 ; each of R.sup.5 and R.sup.6, independently, is H, CHO, COR.sup.1, COOH, COOR.sup.9, CN, or halogen; R.sup.7 is H, C.sub.1-4 alkyl, 2-thienyl, phenyl, mono-substituted phenyl, or di-substituted phenyl; R.sup.8 is COOR.sup.2, CO.CHO, C.sub.1-4 hydroxyalkyl or its acid ester or 2-tetrahydropyranyl ether; and R.sup.9 is H, C.sub.1-4 alkyl, phenyl, mono-substituted phenyl, di-substituted phenyl, or 2-thienyl.

  治疗肿瘤的方法包括向受试者施用以下式的化合物的有效量：##STR1## 其中m为1-4；A和B中的每一个独立地为H、C.sub.1-7烷基、C.sub.2-7烯基、C.sub.2-7炔基、(CH.sub.2).sub.nCHO、(CH.sub.2).sub.oCOOH、C.sub.1-7烷氧基、C.sub.2-7烷氧基烷基、C.sub.1-7羟基烷基、CN、NO.sub.2、卤素、CH(OR^1).sub.2、CO.R^1、NR^2R^3或其酸盐、CO.NR^2R^3、CHR^1NR^2R^3或其酸盐、CH.dbd.NR^2、C.tbd.CR^4、CR^1.dbd.CR^5R^6、CO.CH.dbd.CHR^7、CH.dbd.CHR^8或COOR^9；其中n和o中的每一个独立地为0-4；R^1为C.sub.1-4烷基或C.sub.1-4酰基；R^2和R^3中的每一个独立地为H、C.sub.1-4烷基或C.sub.1-4羟基烷基；R^4为H、C.sub.1-4烷基、C.sub.2-4烯基、COR^2、COOR^10、C.sub.1-4羟基烷基或其酸酯或2-四氢吡喃基醚、C.sub.1-4二羟基烷基或其酸酯或2-四氢吡喃基醚、C.sub.1-4卤代烷基；OR^1或NHR^7；R^5和R^6中的每一个独立地为H、CHO、COR^1、COOH、COOR^9、CN或卤素；R^7为H、C.sub.1-4烷基、2-噻吩基、苯基、单取代苯基或双取代苯基；R^8为COOR^2、CO.CHO、C.sub.1-4羟基烷基或其酸酯或2-四氢吡喃基醚；R^9为H、C.sub.1-4烷基、苯基、单取代苯基、双取代苯基或2-噻吩基。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX
  申请人：Deng Huayun

  公开号：US20120022116A1

  公开（公告）日：2012-01-26

  Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):

  揭示了与GPR35及/或GPR35-hERG信号复合物在病理生理上相关的疾病的预防和/或治疗的组合物和方法。例如，揭示了用于预防和/或治疗与GPR35在受试者中病理生理相关的疾病的化合物。这些化合物具有以下公式(I)、(II)或(III)：
• SUBSTITUTED PYRAZOLE DERIVATIVES
  申请人：ITO Mitsuhiro

  公开号：US20090270359A1

  公开（公告）日：2009-10-29

  The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R 1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R 3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

  本发明提供一种新型吡唑衍生物和含有该衍生物的雄激素受体拮抗剂。本发明提供一种由下式表示的化合物(I′)：其中R1是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R2是苯基，带有氰基（苯基可能还有除氰基之外的取代基）；R3是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R4是可选地带有取代基的环状基团；X是亚甲基，可选地带有取代基，或CO，或其盐。
• Dual-role of PtCl₂ catalysis in the intramolecular cyclization of (hetero)aryl-allenes for the facile construction of substituted 2,3-dihydropyrroles and polyheterocyclic skeletons
  作者：Yan-Yan Zhang、Yin Wei、Xiang-Ying Tang、Min Shi

  DOI：10.1039/c7cc01684k

  日期：——

  A Pt(II)-catalyzed cyclization of (hetero)aryl-allenes has been developed, providing controllable synthesis of substituted 2,3-dihydropyrroles and polyheterocyclic skeletons. Another notable feature of this method is the dual-role of the Pt(II) catalyst: initiation of the migration of the (hetero)arylmethylene group and the subsequent Friedel–Crafts type annulation.

  已经开发了Pt（II）催化的（杂）芳基-丙二烯环化反应，提供了可取代的2,3-二氢吡咯和多杂环骨架的可控合成。该方法的另一个显着特点是Pt（II）催化剂具有双重作用：(杂）芳基亚甲基的迁移开始，随后发生Friedel-Crafts型环空反应。